Introduction Acute graft-versus-host disease (aGvHD) is a major source of mortality following allogeneic hematopoietic cell transplantation (allo-HCT). Standard 1st line therapy for the treatment of aGvHD involves corticosteroids (CS). However, more than 50% of patients are refractory to CS (SR-aGvHD) and the associated mortality rate is of up...
-
November 15, 2022 (v1)Journal articleUploaded on: March 25, 2023
-
September 2024 (v1)Journal article
International audience
Uploaded on: August 30, 2024 -
September 2024 (v1)Journal article
IntroductionWe report clinical outcomes from 140 steroid-refractory (SR) or steroid-dependent (SD) GI-aGvHD patients treated with the pooled allogeneic microbiotherapy MaaT013 as part of the Early Access Program (EAP) in Europe.Patients and MethodsThe 140 patients with SR/SD GI-aGvHD, who had been treated unsuccessfully with 1 to 6 systemic...
Uploaded on: August 30, 2024